Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity

IF 19.8 1区 医学 Q1 CELL & TISSUE ENGINEERING
Jun Shen, Shuzhen Lyu, Yingxi Xu, Shuo Zhang, Li Li, Jinze Li, Junli Mou, Leling Xie, Kejing Tang, Wei Wen, Xuemei Peng, Ying Yang, Yu Shi, Xinjie Li, Min Wang, Xin Li, Jianxiang Wang, Tao Cheng
{"title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","authors":"Jun Shen, Shuzhen Lyu, Yingxi Xu, Shuo Zhang, Li Li, Jinze Li, Junli Mou, Leling Xie, Kejing Tang, Wei Wen, Xuemei Peng, Ying Yang, Yu Shi, Xinjie Li, Min Wang, Xin Li, Jianxiang Wang, Tao Cheng","doi":"10.1016/j.stem.2024.04.012","DOIUrl":null,"url":null,"abstract":"<p>Generation of chimeric antigen receptor macrophages (CAR-Ms) from human pluripotent stem cells (hPSCs) offers new prospects for cancer immunotherapy but is currently challenged by low differentiation efficiency and limited function. Here, we develop a highly efficient monolayer-based system that can produce around 6,000 macrophages from a single hPSC within 3 weeks. Based on CAR structure screening, we generate hPSC-CAR-Ms with stable CAR expression and potent tumoricidal activity <em>in vitro</em>. To overcome the loss of tumoricidal activity of hPSC-CAR-Ms <em>in vivo</em>, we use interferon-γ and monophosphoryl lipid A to activate an innate immune response that repolarizes the hPSC-CAR-Ms to tumoricidal macrophages. Moreover, through combined activation of T cells by hPSC-CAR-Ms, we demonstrate that activating a collaborative innate-adaptive immune response can further enhance the anti-tumor effect of hPSC-CAR-Ms <em>in vivo</em>. Collectively, our study provides feasible methodologies that significantly improve the production and function of hPSC-CAR-Ms to support their translation into clinical applications.</p>","PeriodicalId":9665,"journal":{"name":"Cell stem cell","volume":"86 1","pages":""},"PeriodicalIF":19.8000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell stem cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.stem.2024.04.012","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

Generation of chimeric antigen receptor macrophages (CAR-Ms) from human pluripotent stem cells (hPSCs) offers new prospects for cancer immunotherapy but is currently challenged by low differentiation efficiency and limited function. Here, we develop a highly efficient monolayer-based system that can produce around 6,000 macrophages from a single hPSC within 3 weeks. Based on CAR structure screening, we generate hPSC-CAR-Ms with stable CAR expression and potent tumoricidal activity in vitro. To overcome the loss of tumoricidal activity of hPSC-CAR-Ms in vivo, we use interferon-γ and monophosphoryl lipid A to activate an innate immune response that repolarizes the hPSC-CAR-Ms to tumoricidal macrophages. Moreover, through combined activation of T cells by hPSC-CAR-Ms, we demonstrate that activating a collaborative innate-adaptive immune response can further enhance the anti-tumor effect of hPSC-CAR-Ms in vivo. Collectively, our study provides feasible methodologies that significantly improve the production and function of hPSC-CAR-Ms to support their translation into clinical applications.

Abstract Image

激活先天性免疫反应可使 hPSC 衍生的 CAR 巨噬细胞重新极化,从而提高抗肿瘤活性
从人类多能干细胞(hPSC)中生成嵌合抗原受体巨噬细胞(CAR-Ms)为癌症免疫疗法提供了新的前景,但目前面临着分化效率低和功能有限的挑战。在这里,我们开发了一种基于单层的高效系统,可在 3 周内从单个 hPSC 中产生约 6000 个巨噬细胞。基于 CAR 结构筛选,我们生成了具有稳定 CAR 表达和强大体外杀瘤活性的 hPSC-CAR-Ms。为了克服 hPSC-CAR-Ms 在体内失去杀瘤活性的问题,我们使用干扰素-γ 和单磷脂 A 激活先天性免疫反应,使 hPSC-CAR-Ms 重新极化为具有杀瘤活性的巨噬细胞。此外,通过 hPSC-CAR-Ms 对 T 细胞的联合激活,我们证明了激活协作性先天适应性免疫反应可进一步增强 hPSC-CAR-Ms 在体内的抗肿瘤效果。总之,我们的研究提供了可行的方法,可显著改善 hPSC-CAR-Ms 的生产和功能,支持其转化为临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cell stem cell
Cell stem cell 生物-细胞生物学
CiteScore
37.10
自引率
2.50%
发文量
151
审稿时长
42 days
期刊介绍: Cell Stem Cell is a comprehensive journal covering the entire spectrum of stem cell biology. It encompasses various topics, including embryonic stem cells, pluripotency, germline stem cells, tissue-specific stem cells, differentiation, epigenetics, genomics, cancer stem cells, stem cell niches, disease models, nuclear transfer technology, bioengineering, drug discovery, in vivo imaging, therapeutic applications, regenerative medicine, clinical insights, research policies, ethical considerations, and technical innovations. The journal welcomes studies from any model system providing insights into stem cell biology, with a focus on human stem cells. It publishes research reports of significant importance, along with review and analysis articles covering diverse aspects of stem cell research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信